Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug;30(8):1533-1534.
doi: 10.1002/oby.23525.

Glucagon-like peptide-1 receptor agonists, weight loss, and gastric emptying: have I gut news for you

Ryan J Jalleh  1   2   3   4 , Christopher K Rayner  1   2   5 , Karen L Jones  1   2   3 , Michael Horowitz  1   2   3
Affiliations
Comment

Glucagon-like peptide-1 receptor agonists, weight loss, and gastric emptying: have I gut news for you

Ryan J Jalleh et al. Obesity (Silver Spring). 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ryan J. Jalleh declared no conflict of interest. Christopher K. Rayner has participated in advisory boards for Allergan plc and Glyscend, Inc., for which honoraria were paid, and has received research funding from Merck & Co., Inc., Eli Lilly and Company, Sanofi S.A., AstraZeneca plc, and Novartis International AG. Karen L. Jones has participated in advisory boards for Glyscend, Inc., and has received research funding from Sanofi S.A. and AstraZeneca plc. Michael Horowitz has participated in advisory boards and/or symposia for Novo Nordisk A/S, Sanofi S.A., Novartis International AG, Eli Lilly and Company, Merck & Co., Inc., Boehringer Ingelheim, AstraZeneca plc, and Glyscend, Inc., and has received honoraria.

Comment on

References

    1. Maselli D, Atieh J, Clark MM, et al. Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial. Obesity (Silver Spring). 2022;30:1608‐1620. - PMC - PubMed
    1. Jones KL, Huynh LQ, Hatzinikolas S, et al. Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady‐state concentrations. Diabetes Obes Metab. 2020;22:788‐797. - PubMed
    1. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123‐129. - PubMed
    1. Watson LE, Xie C, Wang X, et al. Gastric emptying in patients with well‐controlled type 2 diabetes compared with young and older control subjects without wiabetes. J Clin Endocrinol Metab. 2019;104:3311‐3319. - PubMed
    1. Jalleh R, Pham H, Marathe CS, et al. Acute effects of lixisenatide on energy intake in healthy subjects and patients with type 2 diabetes: relationship to gastric emptying and intragastric distribution. Nutrients. 2020;12:1962. doi:10.3390/nu12071962 - DOI - PMC - PubMed

LinkOut - more resources